Our Pipeline

At Apellis, we aim to transform treatment across a broad range of debilitating diseases driven by complement.

We brought forward the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved across four diseases. We are advancing that science in multiple clinical and pre-clinical programs in serious diseases with urgent unmet needs.

Ophthalmology

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
SYFOVRE®
(pegcetacoplan injection)
GA Approved Marketed in the US
APL-3007 + SYFOVRE
GA Phase II

RARE DISEASE

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
EMPAVELI®
(pegcetacoplan)*
PNH Approved Marketed in the US
C3G & Primary IC-MPGN Approved Marketed in the US
FSGS Plan to initiate pivotal study in H2 2025
DGF Plan to initiate pivotal study in H2 2025

Neurology

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
RNA therapies
Undisclosed Preclinical

MULTIPLE THERAPEUTIC AREAS

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
Gene-edited FcRn therapy (Beam)
Undisclosed Preclinical
Gene-edited complement therapies (Beam)
Undisclosed Preclinical
Oral complement inhibitor
Undisclosed Preclinical

*Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan

The safety and efficacy of the agents for the indications under investigation have not been established.